Humalog

🚨 Humalog (Eli Lilly) Boycott Reasons and Overview

Humalog is a proprietary pharmaceutical product developed and marketed by the American multinational pharmaceutical titan Eli Lilly and Company. The primary ground for Humalog's inclusion in global consumer boycott directories is parent company Eli Lilly's institutional entrenchment in israel, direct corporate funding to israeli emergency response organizations, and high-level corporate solidarity during military campaigns:

1. Direct Subsidiary and Research Ties in israel: Eli Lilly maintains a wholly owned local operating subsidiary, Eli Lilly israel Ltd., headquartered in Ra'anana. Furthermore, the company has integrated israeli biotechnology assets into its drug development pipeline, including a major R&D pact with Anima Biotech exceeding $1 billion.
2. $500,000 Direct Donation to Magen David Adom (MDA): Through Eli Lilly israel, the corporation donated $500,000 worth of specialized mobile intensive care units (MICUs) and clinical monitoring hardware to Magen David Adom, directly reinforcing israel's national emergency medical and logistical apparatus.
3. Corporate Solidarity and Matching Relief Funds: In October 2023, Eli Lilly issued an executive corporate declaration committing $500,000 in immediate aid to israeli relief entities, complemented by an additional $500,000 employee matching fund from the Lilly Foundation.
4. Targeted by Medical Syndicates & Boycott Coalitions: Medical bodies such as the Arab Doctors Union have formally listed Eli Lilly among multinational pharmaceutical corporations materially supporting the israeli state, prompting calls for ethical procurement.
5. Pharmaceutical Revenues Underwriting Corporate Assets: Global prescriptions and sales of Humalog directly generate corporate revenues and intellectual property dividends that feed Eli Lilly's central treasury and major institutional shareholders (including BlackRock and Vanguard).

Important Medical Advisory: Humalog is a prescription therapeutic. Patients are strongly advised not to discontinue vital prescribed medications without consulting licensed healthcare providers, and to discuss bioequivalent alternatives with their physicians or pharmacists. For complete documentation, corporate filing citations, and historical context, please visit the 👉 Eli Lilly Boycott Dossier.